{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T11:00:52Z","timestamp":1758970852224},"reference-count":75,"publisher":"Informa UK Limited","issue":"3","funder":[{"name":"Skyline DX to perform this study"},{"name":"JG Gaultney was employed at Erasmus University Rotterdam"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Pharmacogenomics"],"published-print":{"date-parts":[[2018,2]]},"DOI":"10.2217\/pgs-2017-0140","type":"journal-article","created":{"date-parts":[[2018,1,15]],"date-time":"2018-01-15T15:59:48Z","timestamp":1516031988000},"page":"213-226","update-policy":"http:\/\/dx.doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":3,"title":["Potential Therapeutic and Economic Value of Risk-Stratified Treatment as Initial Treatment of Multiple Myeloma in Europe"],"prefix":"10.1080","volume":"19","author":[{"given":"Jennifer G","family":"Gaultney","sequence":"first","affiliation":[{"name":"IQVIA, 210 Pentonville Road, LondonN1 9JY, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Therese W","family":"Ng","sequence":"additional","affiliation":[{"name":"IQVIA, 210 Pentonville Road, LondonN1 9JY, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carin A","family":"Uyl-de Groot","sequence":"additional","affiliation":[{"name":"Erasmus School of Health Policy &amp; Management, Institute for Medical Technology Assessment, Erasmus University Rotterdam, Rotterdam, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pieter","family":"Sonneveld","sequence":"additional","affiliation":[{"name":"Department of Haematology, Erasmus MC Cancer Institute, P.O. Box\u00a02040, 3000 CA, Rotterdam, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erik H","family":"van Beers","sequence":"additional","affiliation":[{"name":"SkylineDx BV, Rotterdam Science Tower, Marconistraat 16, 18th floor\u00a03029AKRotterdam, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin H","family":"van Vliet","sequence":"additional","affiliation":[{"name":"SkylineDx BV, Rotterdam Science Tower, Marconistraat 16, 18th floor\u00a03029AKRotterdam, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William K","family":"Redekop","sequence":"additional","affiliation":[{"name":"Erasmus School of Health Policy &amp; Management, Institute for Medical Technology Assessment, Erasmus University Rotterdam, Rotterdam, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2018,1,15]]},"reference":[{"key":"e_1_3_4_3_1","unstructured":"Cancer Research United Kingdom (UK) . Myeloma incidence statistics (19 May 2017) ( 2014 ). www.cancerresearchuk.org\/"},{"key":"e_1_3_4_4_1","unstructured":"Eucan Factsheets . Multiple myeloma and immunoproliferative diseases: estimated incidence mortality and prevalence for both sexes ( 2012 ). http:\/\/eco.iarc.fr\/EUCAN\/Cancer.aspx?Cancer=39"},{"key":"e_1_3_4_5_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-05-432203"},{"key":"e_1_3_4_6_1","unstructured":"National Institute for Health and Care Excellence (NICE) . Bortezomib for induction therapy in multiple myeloma before high-dose chemotherapy and autologous stem cell transplantation: technology appraisal guidance ( 2014 ). www.nice.org.uk\/guidance\/TA311"},{"key":"e_1_3_4_7_1","unstructured":"National Institute for Health and Care Excellence (NICE) . Multiple myeloma: diagnosis and management ( 2016 ). www.nice.org.uk\/guidance\/ng35"},{"key":"e_1_3_4_8_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx096"},{"key":"e_1_3_4_9_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.61.2267"},{"key":"e_1_3_4_10_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-01-631200"},{"key":"e_1_3_4_11_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2404516"},{"key":"e_1_3_4_12_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2012.127"},{"key":"e_1_3_4_13_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-05-644039"},{"key":"e_1_3_4_14_1","volume-title":"European Hematology Association Poster Area","author":"Van Vliet MH","year":"2016","unstructured":"Van Vliet MH , KuiperR , UbelsJet al. The SKY92 prognostic marker is validated in eight multiple myeloma clinical datasets . Presented at : European Hematology Association Poster Area , 10 June 2017 ( 2016 )."},{"key":"e_1_3_4_15_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-06-297853"},{"key":"e_1_3_4_16_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.39.6820"},{"key":"e_1_3_4_17_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2008.88"},{"key":"e_1_3_4_18_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2016.380"},{"key":"e_1_3_4_19_1","doi-asserted-by":"publisher","DOI":"10.3390\/toxics3030294"},{"key":"e_1_3_4_20_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-15-3163"},{"key":"e_1_3_4_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(10)70206-0"},{"key":"e_1_3_4_22_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V128.22.5960.5960"},{"key":"e_1_3_4_23_1","article-title":"W2: Using early economic models to guide clinical and commercial development of new therapies","author":"Lucas F","year":"2013","unstructured":"Lucas F , TaylorM , BlankenburgM . W2: Using early economic models to guide clinical and commercial development of new therapies . ISPOR 16th Annual European Congress ( 2013 ).","journal-title":"ISPOR 16th Annual European Congress"},{"key":"e_1_3_4_24_1","unstructured":"Zorginstituut Nederland (ZiN) . Medicijnkosten ( 2017 ). www.medicijnkosten.nl\/"},{"key":"e_1_3_4_25_1","unstructured":"Rote Liste Service Gmbh. Red List [Rote Liste] ( 2017 ). www.rote-liste.de\/"},{"key":"e_1_3_4_26_1","unstructured":"National Institute of Health and Care Excellence (NICE) . British National Formulary. February ( 2017 )."},{"key":"e_1_3_4_27_1","unstructured":"National Health Insurance Fund of Employees [Caisse Nationale De L\u2019assurance Maladie Des Travailleurs Salari\u00e9s C]. . Drug Base and information Tariff [Base des medicaments et informations tarifaires] ( 2017 )."},{"key":"e_1_3_4_28_1","unstructured":"Agence technique de l\u2019information sur l\u2019hospitalisation (ATIH) . Tarifs MCO et HAD\u2013Groupe Homogene de Sejour . ( 2017 )."},{"key":"e_1_3_4_29_1","unstructured":"Spanish Medicine and Health Products Agency [Agencia Espanola De Medicamentos Y Productos Santarios] . AEMPS Medicines Online Information Center\u2013CIMA. March ( 2017 ). www.aemps.gob.es\/cima\/pestanias.do?metodo=accesoAplicacion"},{"key":"e_1_3_4_30_1","unstructured":"Genesis [Sociedad Espanola De Farmacia Hospitalaria] . Summary of hospital reports ( 2017 ). http:\/\/gruposdetrabajo.sefh.es\/genesis\/index.php?option=com_content&view=article&id=16&Itemid=19"},{"key":"e_1_3_4_31_1","unstructured":"Hakkaart-van Roijen L van der LindenN BouwmansC KantersT TanS . Dutch manual for costing: methods and reference prices for economic evaluations in healthcare updated version [Handleiding voor kostenonderzoek: Methoden en referentieprijzen voor economische evaluaties in de gezondheidszorg. Zorginstituut Nederland. Geactualiseerde versie 2015] ( 2015 )."},{"key":"e_1_3_4_32_1","unstructured":"UK Department of Health . National schedule of reference costs. 2015\u20132016 ( 2016 )."},{"key":"e_1_3_4_33_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdq759"},{"key":"e_1_3_4_34_1","doi-asserted-by":"publisher","DOI":"10.1185\/03007990903209563"},{"key":"e_1_3_4_35_1","unstructured":"Organisation for economic co-operation and development (OECD) . Consumer prices index. 10 January 2017 . http:\/\/stats.oecd.org\/Index.aspx?DatasetCode=MEI_PRICES"},{"key":"e_1_3_4_36_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-012-1530-2"},{"key":"e_1_3_4_37_1","unstructured":"Ortega Ortega M . An\u00e1lisis de costes sanitarios y no sanitarios asociados al tratamiento oncol\u00f3gico en pacientes con neoplasia hematol\u00f3gica desde una perpectiva econ\u00f3mica [PhD thesis] . Universidad De Granada Granada Spain ( 2015 )."},{"key":"e_1_3_4_38_1","unstructured":"German Hospital Service . Price estimates for hospital services in Germany [Diagnosis Related Groups] ( 2017 ). www.drg.german-hospital-service.com\/"},{"key":"e_1_3_4_39_1","unstructured":"L\u2019Agence technique de l\u2019information sur l\u2019hospitalisation (ATIH) . Tarifs MCO et HAD\u2013GHS 8977 autogreffes de cellules souches h\u00e9matopo\u00ef\u00e9tiques ( 2017 ). http:\/\/atih.sante.fr\/tarifs-mco-et-had"},{"key":"e_1_3_4_40_1","unstructured":"Dutch Healthcare Authority [Nederlandse Zorgautoriteit (Nza)] . DBC Healthcare product tariff application [DBC Zorgproducten Tariefapplicatie] ( 2017 ). http:\/\/dbc-zorgproducten-tarieven.nza.nl\/nzaZpTarief\/Error.aspx?aspxerrorpath=\/nzaZpTarief\/ZoekfunctieDot.aspx.%20Product%20code:%20%20191140.%20Description%20in%20Dutch:%20[Algemeen%20chromosoomonderzoek%20voor%20identificatie%20van%20numerieke%20en%20structurele%20afwijkingen%20d.m.v.%20karyotypering.]%20January%202017"},{"key":"e_1_3_4_41_1","unstructured":"Health Insurance [Kassenarztliche Bundesvereinigung] . Uniform evaluation [Einheitlicher bewertungsmassstab (EBM)]. February ( 2017 ). www.kbv.de\/html\/ebm.php"},{"key":"e_1_3_4_42_1","unstructured":"National Health Insurance Fund of Employees [Caisse Nationale De L\u2019assurance Maladie Des Travailleurs Salari\u00e9s] . Medical Biology: Nomenclature of Acts ( 2017 ). www.codage.ext.cnamts.fr\/f_mediam\/fo\/nabm\/DOC044.pdf"},{"key":"e_1_3_4_43_1","unstructured":"Great Ormond Street Hospital for Children . Genetics Price List. 2014\u20132015 ( 2017 ). www.labs.gosh.nhs.uk\/media\/534948\/nhs_joint_price_list_201415_dec14.pdf"},{"key":"e_1_3_4_44_1","unstructured":"Cidegen Sl . Cytogenetics price list ( 2017 ). www.cidegen.com"},{"key":"e_1_3_4_45_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2008.07573.x"},{"key":"e_1_3_4_46_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10198-015-0757-y"},{"key":"e_1_3_4_47_1","doi-asserted-by":"publisher","DOI":"10.1111\/jcpt.12020"},{"key":"e_1_3_4_48_1","article-title":"Healthcare resource utilization in relapsed\/refractory multiple myeloma: comparison of EU and US cohorts in the PREAMBLE study","author":"Vij R","year":"2016","unstructured":"Vij R , ZyczynskiT , DaumontMet al. Healthcare resource utilization in relapsed\/refractory multiple myeloma: comparison of EU and US cohorts in the PREAMBLE study . ISPORPCN192 ( 2016 ).","journal-title":"ISPOR"},{"key":"e_1_3_4_49_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2004.01.019"},{"key":"e_1_3_4_50_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejpain.2005.01.014"},{"key":"e_1_3_4_51_1","unstructured":"Zorginstituut Nederland (ZiN) . Guidelines for economic evaluations in healthcare ( 2016 ). https:\/\/english.zorginstituutnederland.nl\/publications\/reports\/2016\/06\/16\/guideline-for-economic-evaluations-in-healthcare"},{"key":"e_1_3_4_52_1","unstructured":"International Society for Pharmacoeconomics and Outcomes Research (ISPOR) . Pharmacoeconomic guidelines around the world: Spain . ( 2016 ). www.ispor.org\/PEguidelines\/countrydet.asp?c=20&t=4"},{"key":"e_1_3_4_53_1","unstructured":"Institute for quality and efficiency in health care (IQWiG) . General Methods 4.2 . ( 2015 ). www.iqwig.de\/download\/IQWiG_General_Methods_Version_%204-2.pdf"},{"key":"e_1_3_4_54_1","unstructured":"Haute autorite de sante (HAS) . Choices in methods for economic evaluation ( 2012 ). www.has-sante.fr\/portail\/upload\/docs\/application\/pdf\/2012-10\/choices_in_methods_for_economic_evaluation.pdf"},{"key":"e_1_3_4_55_1","volume-title":"Guide to the methods of technology appraisal","year":"2013","unstructured":"National Institute of Health and Care Excellence (NICE) . Guide to the methods of technology appraisal . ( 2013 )."},{"key":"e_1_3_4_56_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V126.23.2970.2970"},{"key":"e_1_3_4_57_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30206-6"},{"key":"e_1_3_4_58_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.23546"},{"key":"e_1_3_4_59_1","doi-asserted-by":"publisher","DOI":"10.2217\/pgs.10.187"},{"key":"e_1_3_4_60_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40273-012-0017-2"},{"key":"e_1_3_4_61_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.hlpt.2014.08.004"},{"key":"e_1_3_4_62_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2013.313"},{"key":"e_1_3_4_63_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.mayocp.2013.01.019"},{"key":"e_1_3_4_64_1","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2017.0023"},{"key":"e_1_3_4_65_1","doi-asserted-by":"publisher","DOI":"10.1080\/14712598.2017.1322578"},{"key":"e_1_3_4_66_1","first-page":"1","article-title":"The hematologic drug pipeline: exciting new treatment options looming","volume":"9","author":"Starr P","year":"2016","unstructured":"Starr P . The hematologic drug pipeline: exciting new treatment options looming . Am. Health Drug Benefits9 ( Spec. Issue ), 1 \u2013 20 ( 2016 ).","journal-title":"Am. Health Drug Benefits"},{"key":"e_1_3_4_67_1","first-page":"4358","article-title":"MMprofiler with SKY92 combined with ISS identifies high and low risk multiple myeloma in the VTD arm of Gimema-MMY-3006","volume":"130","author":"Van Beers E","year":"2017","unstructured":"Van Beers E , TerragnaC , MartelloMet al. MMprofiler with SKY92 combined with ISS identifies high and low risk multiple myeloma in the VTD arm of Gimema-MMY-3006 . Am. Soc. Hematol.130 , 4358 ( 2017 ).","journal-title":"Am. Soc. Hematol."},{"key":"e_1_3_4_68_1","unstructured":"German health insurance [Dkv: Deutsche Krankenversicherung]. Drug price comparison ( February 2017 )."},{"key":"e_1_3_4_69_1","unstructured":"Agence technique de l\u2019information sur l\u2019hospitalisation (ATIH) . Tarifs MCO et HAD\u2013GHS Chimioth\u00e9rapie pour autre tumeur ( 2017 )."},{"key":"e_1_3_4_70_1","unstructured":"l\u2019Assurance Maladie . Base des M\u00e9dicaments et Information Tarifaires\u2013Velcade 3.5mg (10\/01\/2017) ."},{"key":"e_1_3_4_71_1","unstructured":"Pharmacy College of Pontevedra [Colegio De Farmaceuticos De Pontevedra]. Medication pricing query [Consulta de Precios de Medicamentos] ( 2015 )."},{"key":"e_1_3_4_72_1","unstructured":"General Council of Official Pharmacy Colleges [Consejo General De Colegios Oficiales De Farmaceuticos]. Bot Plus 2.0 ( 2013 )."},{"key":"e_1_3_4_73_1","unstructured":"Ministry of Health Social Services and Equality . Billing list of SNS pharmaceutical supply ( 2017 )."},{"key":"e_1_3_4_74_1","unstructured":"Agence technique de l\u2019information sur l\u2019hospitalisation (ATIH) . Tarifs MCO et HAD\u2013GHS 6535 H\u00e9mopathies my\u00e9lo\u00efdes chroniques ( 2017 )."},{"key":"e_1_3_4_75_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1703641"},{"key":"e_1_3_4_76_1","unstructured":"NHS Blood and Transplant . The future of unrelated donor stem cell transplantation in the UK ( 2010 )."},{"key":"e_1_3_4_77_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1705109"}],"container-title":["Pharmacogenomics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.2217\/pgs-2017-0140","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,17]],"date-time":"2024-05-17T21:55:25Z","timestamp":1715982925000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.2217\/pgs-2017-0140"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1,15]]},"references-count":75,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2018,2]]}},"alternative-id":["10.2217\/pgs-2017-0140"],"URL":"https:\/\/doi.org\/10.2217\/pgs-2017-0140","relation":{},"ISSN":["1462-2416","1744-8042"],"issn-type":[{"value":"1462-2416","type":"print"},{"value":"1744-8042","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,1,15]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ipgs20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ipgs20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2017-08-11","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2017-11-13","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-01-15","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}